Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE:TMO) reported strong Q2 2025 financial results with revenue growing 3% to $10.85 billion and GAAP EPS increasing 6% to $4.28. The company's adjusted EPS was $5.36, while adjusted operating margin stood at 21.9%.

During the quarter, TMO launched several next-generation instruments including the Orbitrap Astral Zoom mass spectrometer and Krios 5 Cryo-TEM. The company also expanded its DynaDrive single-use bioreactor portfolio and announced a strategic partnership with Sanofi to acquire its Ridgefield, New Jersey sterile fill-finish site.

The company demonstrated effective cost management through its PPI Business System, enabling strong operational performance despite challenging market conditions.

Thermo Fisher Scientific (NYSE:TMO) has announced an expansion of its strategic partnership with Sanofi through the acquisition of Sanofi's sterile manufacturing facility in Ridgefield, New Jersey. The state-of-the-art sterile fill-finish and packaging facility employs over 200 workers who will join Thermo Fisher upon deal completion.

Under the agreement, Thermo Fisher will continue manufacturing Sanofi's portfolio of therapies while expanding the site's capacity to meet growing U.S. manufacturing demand from pharma and biotech customers. The facility will join TMO's existing sterile fill-finish network, which includes sites in Greenville, North Carolina and Plainville, Massachusetts. The transaction is expected to close in H2 2025, after which the facility will become part of Thermo Fisher's pharma services business.

Thermo Fisher Scientific (NYSE:TMO), a global leader in serving science, has announced a quarterly cash dividend. The company's Board of Directors has declared a dividend of $0.43 per common share. The dividend will be paid on October 15, 2025, to shareholders who are on record as of September 15, 2025.

Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, has scheduled its second quarter 2025 earnings conference call for Wednesday, July 23, 2025, at 8:30 a.m. ET. The company will release its financial results before the market opens on the same day.

Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S., using access code 523661. A live webcast will be available on the "Investors" section of www.thermofisher.com. The earnings release and related materials will be posted under the "Financials" section. A replay will remain accessible through October 21, 2025.

Thermo Fisher Scientific (NYSE: TMO) has unveiled two groundbreaking mass spectrometers at ASMS 2025: the Orbitrap Astral Zoom and Orbitrap Excedion Pro. The Orbitrap Astral Zoom delivers 35% faster scan speeds, 40% higher throughput, and 50% expanded multiplexing capabilities, enhancing sensitivity and experimental flexibility for proteomics research. The Orbitrap Excedion Pro, designed for biopharma applications, is the first platform combining next-generation Orbitrap hybrid mass spectrometry with alternative fragmentation technologies, accelerating biological drug development particularly for monoclonal antibodies. These innovations aim to advance precision medicine and research in complex diseases like Alzheimer's and cancer, while strengthening Thermo Fisher's position in omics and proteomics research solutions.

Thermo Fisher Scientific (NYSE: TMO) has announced a quarterly cash dividend payment. The company's Board of Directors has approved a dividend of $0.43 per common share. The dividend will be paid on July 15, 2025, to shareholders who are registered as of the record date June 13, 2025.

Thermo Fisher Scientific (NYSE: TMO) announced that its Chairman, President and CEO Marc N. Casper will present at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. ET. Investors can access the live webcast of the presentation through the Investors section of Thermo Fisher's website at www.thermofisher.com.

Thermo Fisher Scientific (NYSE: TMO) has announced a $2 billion investment in the United States over the next four years to strengthen American innovation, manufacturing, and economic competitiveness in the life sciences sector. The investment includes $1.5 billion in capital expenditures to enhance U.S. manufacturing operations and $500 million in R&D for high-impact innovation.

The company currently operates 64 U.S. manufacturing facilities across 37 states, producing analytical instruments, specialty diagnostics, and life sciences solutions. Since 2017, Thermo Fisher has experienced significant growth, doubling from $21 billion in revenue and 28,000 U.S. employees to $43 billion in revenue and over 50,000 U.S. employees today. The company currently invests $1 billion annually in U.S. R&D.

Thermo Fisher Scientific (NYSE: TMO) reported its Q1 2025 financial results with revenue of $10.36 billion, showing minimal growth from $10.34 billion in Q1 2024. The company achieved 1% organic revenue growth and a 15% increase in GAAP EPS to $3.98, while adjusted EPS grew 1% to $5.15.

Key Q1 highlights include the launch of innovative products such as the Vulcan Automated Lab for semiconductor analysis, Olink Reveal proteomics kits, and new centrifuge systems. The company executed significant capital deployment initiatives, including a $4.1 billion agreement to acquire Solventum's Purification & Filtration Business, $2.0 billion in stock repurchases, and a 10% dividend increase.

Operating metrics showed GAAP operating margin of 16.6% (up from 16.1% in Q1 2024) and adjusted operating margin of 21.9% (slightly down from 22.0% in Q1 2024).